Your browser doesn't support javascript.
loading
Retrospective characterization of nodal marginal zone lymphoma.
Stuver, Robert; Drill, Esther; Qualls, David; Okwali, Michelle; Lee Batlevi, Connie; Caron, Philip C; Dogan, Ahmet; Epstein-Peterson, Zachary D; Falchi, Lorenzo; Hamlin, Paul A; Horwitz, Steven M; Imber, Brandon S; Intlekofer, Andrew M; Johnson, William T; Khan, Niloufer; Kumar, Anita; Lahoud, Oscar B; Lue, Jennifer Kimberly; Matasar, Matthew J; Moskowitz, Alison J; Noy, Ariela; Owens, Colette N; Palomba, M Lia; Schöder, Heiko; Vardhana, Santosha A; Yahalom, Joachim; Zelenetz, Andrew D; Salles, Gilles; Straus, David J.
Afiliación
  • Stuver R; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Drill E; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Qualls D; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Okwali M; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Lee Batlevi C; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Caron PC; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Dogan A; Department of Pathology and Laboratory Medicine, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Epstein-Peterson ZD; Department of Medicine, Weill Cornell Medical College, New York, NY.
  • Falchi L; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Hamlin PA; Department of Medicine, Weill Cornell Medical College, New York, NY.
  • Horwitz SM; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Imber BS; Department of Medicine, Weill Cornell Medical College, New York, NY.
  • Intlekofer AM; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Johnson WT; Department of Medicine, Weill Cornell Medical College, New York, NY.
  • Khan N; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Kumar A; Department of Medicine, Weill Cornell Medical College, New York, NY.
  • Lahoud OB; Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Lue JK; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Matasar MJ; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Moskowitz AJ; Department of Medicine, Weill Cornell Medical College, New York, NY.
  • Noy A; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Owens CN; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Palomba ML; Department of Medicine, Weill Cornell Medical College, New York, NY.
  • Schöder H; Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Vardhana SA; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Yahalom J; Department of Medicine, Weill Cornell Medical College, New York, NY.
  • Zelenetz AD; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Salles G; Department of Medicine, Weill Cornell Medical College, New York, NY.
  • Straus DJ; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Blood Adv ; 7(17): 4838-4847, 2023 09 12.
Article en En | MEDLINE | ID: mdl-37307213
Nodal marginal zone lymphoma (NMZL) is a rare non-Hodgkin B-cell lymphoma that has historically been difficult to define, though is now formally recognized by the World Health Organization Classification. To better characterize the clinical outcomes of patients with NMZL, we reviewed a sequential cohort of 187 patients with NMZL to describe baseline characteristics, survival outcomes, and time-to-event data. Initial management strategies were classified into five categories: observation, radiation, anti-CD20 monoclonal antibody therapy, chemoimmunotherapy, or other. Baseline Follicular Lymphoma International Prognostic Index scores were calculated to evaluate prognosis. A total of 187 patients were analyzed. The five-year overall survival was 91% (95% confidence interval [CI], 87-95), with a median follow-up time of 71 months (range, 8-253) among survivors. A total of 139 patients received active treatment at any point, with a median follow-up time of 56 months (range, 13-253) among survivors who were never treated. The probability of remaining untreated at five years was 25% (95% CI, 19-33). For those initially observed, the median time to active treatment was 72 months (95% CI, 49-not reached). For those who received at least one active treatment, the cumulative incidence of receiving a second active treatment at 60 months was 37%. Transformation to large B-cell lymphoma was rare, with a cumulative incidence of 15% at 10 years. In summary, our series is a large cohort of uniformly diagnosed NMZL with detailed analyses of survival and time to event analyses. We showed that NMZL commonly presents as an indolent lymphoma for which initial observation is often a reasonable strategy.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B de la Zona Marginal / Antineoplásicos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Blood Adv Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B de la Zona Marginal / Antineoplásicos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Blood Adv Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos